Navigation Links
FirstMark Announces New Hire Jay Houtman as Southeast Regional Sales Manager

SAN DIEGO and DALLAS, April 3, 2012 /PRNewswire-iReach/ -- FirstMark today announced the appointment of Jay Houtman as the company's new Regional Sales Manager for the Southeast region of the United States. Houtman will be based out of Dallas Texas. His primary role will be to drive growth and awareness for FirstMark's new cardiovascular test PREvent. PREvent is a simple blood test that distinguishes the top 5 percent of suspected or confirmed coronary artery disease patients that are at a 5.5 times greater risk of a near term (2-3 years) heart attack.

"Heart disease is the number one cause of death in the U.S. There is a pervasive need for PREvent to identify patients at risk in the Southeast region of the country. I am confident that Jay will help infuse FirstMark with strong, disciplined professional sales management to support our corporate growth initiatives for PREvent, while building and fostering strong relationships with physicians in this territory," said Thomas Silberg, President and CEO of GenWay Biotech.

Houtman brings a unique depth of experience in sales, customer service, training and technical expertise in cardiovascular and oncology, diagnostic and pharmaceutical solutions. Previous experience includes sales management positions with Bristol-Myers Squibb, Sanofi-Aventis and Gambro. He has consistently ranked with these companies as first in the nation and various regions for sales performance and customer service. Houtman received his B.S. in Health Sciences from the University of Oklahoma.

"The opportunity with FirstMark is phenomenal," said Houtman. "It isn't often that a novel test like this comes along that is so rich in data and supported by leading cardiologists. I am thrilled to have the opportunity to represent PREvent and its potential to save lives from heart attacks."

About PREvent

PREvent is the first and only multiple biomarker blood test on the market that accurately predicts the risk of near term (2-3 years) myocardial infarction or death in patients with suspected or confirmed, insignificant or significant coronary artery disease. Research has discovered that there are multiple pathways that lead to formation of vulnerable plaques. PREvent aggregates three cardiovascular biomarkers that identify these pathways, and projects the propensity for an individual to develop vulnerable plaque. PREvent provides physician's diagnostic clarity in identifying CAD patients that are in most urgent need of aggressive treatment, compliance and monitoring.

About FirstMark

FirstMark is a division of GenWay Biotech, Inc. The FirstMark division is focused on the development and commercialization of non-invasive diagnostic and health monitoring tests for unmet clinical needs. Headquarters are located in the heart of San Diego's biotech community in the Sorrento Valley/Mesa area. For additional information please visit

Media Contact:

Deborah Moore GenWay Biotech, 858-458-0866,

News distributed by PR Newswire iReach:

SOURCE FirstMark
Copyright©2010 PR Newswire.
All rights reserved

Related biology news :

1. Improved Authentication and Confidentiality Protection. ICAP Patent Brokerage Announces for Auction Important Patents in Data Encryption and Document Security
2. ChromaDex® Announces Financial Results for the Year Ended 2011
3. Modern Mobility Aids, Inc. Announces a Revised Agreement for the Acquisition of Lumigene
4. Pew announces 2012 recipients of distinguished Marine Conservation Fellowship
5. PNAS announces 6 2011 Cozzarelli Prize recipients
6. ChromaDex® Announces Management Changes
7. Collaborative Health Consortium Announces eCollaboration Forum Final Agenda for HIMSS 2012
8. Medbox, Inc. Announces New Product Line for 2012
9. FASEB SRC announces conference registration open for: Virus Structure and Assembly
10. Elsevier announces publishing the Ocular Surface
11. Biophysical Society announces New and Notable Symposium speakers
Post Your Comments:
(Date:11/10/2015)... 2015 About signature verification ... to identify and verify the identity of an ... the secure and accurate method of authentication and ... individual because each individual,s signature is highly unique. ... dynamic signature of an individual is compared and ...
(Date:10/29/2015)... Oct. 29, 2015   MedNet Solutions , an ... spectrum of clinical research, is pleased to announce that ... Association (MHTA) as one of only three finalists for ... – Small and Growing" category. The Tekne Awards honor ... shown superior technology innovation and leadership. ...
(Date:10/29/2015)... , October 29, 2015 ... authentication company focused on the growing mobile commerce ... announces that StackCommerce, a leading marketplace to discover ... the Wocket® smart wallet on StackSocial for this ... ("NXT-ID" or the "Company"), a biometric authentication company ...
Breaking Biology News(10 mins):
(Date:11/25/2015)... , November 25, 2015 ... cat and human plaque and pave the way for more ... problems in cats     --> ... most commonly diagnosed health problems in cats, yet relatively little ... now. Two collaborative studies have been conducted by researchers from ...
(Date:11/25/2015)... Orexigen® Therapeutics, Inc. (Nasdaq: OREX ) ... chat discussion at the Piper Jaffray 27th Annual Healthcare ... discussion is scheduled for Wednesday, December 2, at 8:00 ... replay will be available for 14 days after the ... NormartVP, Corporate Communications and Business Development , BrewLife(858) 875-8629 ...
(Date:11/24/2015)... , Nov. 24, 2015 Cepheid (NASDAQ: ... be speaking at the following conference, and invited investors ... York, NY      Tuesday, December 1, 2015 at ... York, NY      Tuesday, December 1, 2015 at ... Healthcare Conference, New York, NY ...
(Date:11/24/2015)... , Nov. 24, 2015 /PRNewswire/ - Aeterna Zentaris Inc. ... IIROC on behalf of the Toronto Stock Exchange, confirms ... there are no corporate developments that would cause the ... --> --> About Aeterna Zentaris ... . --> Aeterna Zentaris is a specialty ...
Breaking Biology Technology: